Albert Lowe
Stock Analyst at Craig-Hallum
(4.02)
# 1,686
Out of 4,468 analysts
135
Total ratings
45.8%
Success rate
11.1%
Average return
Main Sectors:
Stocks Rated by Albert Lowe
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PVLA Palvella Therapeutics | Reiterated: Buy | $205 | $146.76 | +39.68% | 6 | Jun 22, 2026 | |
| IRD Opus Genetics | Maintained: Buy | n/a | $4.23 | - | 10 | Jun 16, 2026 | |
| SABS SAB Biotherapeutics | Maintained: Buy | $6 | $3.92 | +53.06% | 10 | Jun 16, 2026 | |
| CRDF Cardiff Oncology | Downgraded: Hold | $2 | $1.27 | +57.48% | 13 | Jun 4, 2026 | |
| NGNE Neurogene | Maintained: Buy | $65 | $35.34 | +83.93% | 6 | May 15, 2026 | |
| ACTU Actuate Therapeutics | Maintained: Buy | $25 → $12 | $1.52 | +689.47% | 9 | May 12, 2026 | |
| CMPX Compass Therapeutics | Maintained: Buy | n/a | $2.27 | - | 6 | May 6, 2026 | |
| TSX: EPRX Eupraxia Pharmaceuticals Inc. | Reiterated: Buy | $19.91 | $9.45 | +110.65% | 12 | May 5, 2026 | |
| SPRB Spruce Biosciences | Initiated Coverage: Buy | $140 | $52.51 | +166.62% | 1 | Apr 27, 2026 | |
| RMNI Rimini Street | Maintained: Buy | n/a | $4.55 | - | 1 | Apr 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $0.7005 | - | 16 | Mar 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $2 → $4 | $4.91 | -18.53% | 15 | Feb 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 | $2.12 | +371.70% | 7 | Feb 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $3.95 | - | 6 | Jan 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $15.17 | - | 1 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $3 | $1.35 | +122.22% | 7 | Nov 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $4 | $1.22 | +227.87% | 7 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $11.20 | n/a | 1 | Jun 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $14 | $333.36 | n/a | 1 | Jun 4, 2024 |
Palvella Therapeutics
Jun 22, 2026
Reiterated: Buy
Price Target: $205
Current: $146.76
Upside: +39.68%
Opus Genetics
Jun 16, 2026
Maintained: Buy
Price Target: n/a
Current: $4.23
Upside: -
SAB Biotherapeutics
Jun 16, 2026
Maintained: Buy
Price Target: $6
Current: $3.92
Upside: +53.06%
Cardiff Oncology
Jun 4, 2026
Downgraded: Hold
Price Target: $2
Current: $1.27
Upside: +57.48%
Neurogene
May 15, 2026
Maintained: Buy
Price Target: $65
Current: $35.34
Upside: +83.93%
Actuate Therapeutics
May 12, 2026
Maintained: Buy
Price Target: $25 → $12
Current: $1.52
Upside: +689.47%
Compass Therapeutics
May 6, 2026
Maintained: Buy
Price Target: n/a
Current: $2.27
Upside: -
Eupraxia Pharmaceuticals Inc.
May 5, 2026
Reiterated: Buy
Price Target: $19.91
Current: $9.45
Upside: +110.65%
Spruce Biosciences
Apr 27, 2026
Initiated Coverage: Buy
Price Target: $140
Current: $52.51
Upside: +166.62%
Rimini Street
Apr 2, 2026
Maintained: Buy
Price Target: n/a
Current: $4.55
Upside: -
Mar 11, 2026
Maintained: Hold
Price Target: n/a
Current: $0.7005
Upside: -
Feb 17, 2026
Maintained: Hold
Price Target: $2 → $4
Current: $4.91
Upside: -18.53%
Feb 12, 2026
Maintained: Buy
Price Target: $10
Current: $2.12
Upside: +371.70%
Jan 23, 2026
Maintained: Buy
Price Target: n/a
Current: $3.95
Upside: -
Jan 12, 2026
Maintained: Buy
Price Target: n/a
Current: $15.17
Upside: -
Nov 25, 2025
Reiterated: Buy
Price Target: $3
Current: $1.35
Upside: +122.22%
Nov 13, 2025
Maintained: Buy
Price Target: $4
Current: $1.22
Upside: +227.87%
Jun 6, 2024
Maintained: Buy
Price Target: n/a
Current: $11.20
Upside: n/a
Jun 4, 2024
Initiated Coverage: Buy
Price Target: $14
Current: $333.36
Upside: n/a